Indication
Myasthenia gravis
Myasthenia gravis is a chronic autoimmune neuromuscular junction disorder characterized by fluctuating weakness and abnormal fatigability of voluntary skeletal muscles. Read more about Myasthenia gravis
34 drugs 23 manufacturers
Drugs that treat it
Common Myasthenia gravis therapies.
SOLIRIS (eculizumab)
MESTINON (pyridostigmine bromide)
MESTINON (pyridostigmine bromide)
MESTINON (pyridostigmine bromide)
PYRIDOSTIGMINE BROMIDE
PYRIDOSTIGMINE BROMIDE
PYRIDOSTIGMINE BROMIDE
PYRIDOSTIGMINE BROMIDE ER (pyridostigmine bromide)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMyasthenia gravis is a chronic autoimmune neuromuscular junction disorder characterized by fluctuating weakness and abnormal fatigability of voluntary skeletal muscles.
The condition is mediated primarily by pathogenic autoantibodies directed against acetylcholine receptors or related proteins at the postsynaptic motor endplate, disrupting normal neuromuscular transmission.
Clinically, symptoms typically worsen with repeated muscle use and improve with rest, frequently involving the ocular, bulbar, limb, or respiratory muscles.
Presentations range from localized ocular manifestations, such as ptosis and diplopia, to severe generalized weakness that can culminate in life-threatening respiratory failure known as a myasthenic crisis.
- nih.gov
Myasthenia gravis is a chronic autoimmune neuromuscular junction disorder characterized by fluctuating weakness and abnormal fatigability of voluntary skeletal muscles The condition is mediated primarily by pathogenic autoantibodies directed against acetylcholine receptors or related proteins at the postsynaptic motor endplate, disrupting normal neuromuscular transmission Clinically, symptoms typically worsen with repeated muscle use and improve with rest, frequently involving the ocular, bulbar...
- nih.gov
Myasthenia gravis is a chronic autoimmune neuromuscular junction disorder characterized by fluctuating weakness and abnormal fatigability of voluntary skeletal muscles Clinically, symptoms typically worsen with repeated muscle use and improve with rest, frequently involving the ocular, bulbar, limb, or respiratory muscles Presentations range from localized ocular manifestations, such as ptosis and diplopia, to severe generalized weakness that can culminate in life-threatening respiratory failure...
- medlineplus.gov
The condition is mediated primarily by pathogenic autoantibodies directed against acetylcholine receptors or related proteins at the postsynaptic motor endplate, disrupting normal neuromuscular transmission
Personalize your experience
Follow Myasthenia gravis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.